Health In Tech (HIT) Q1 2026 earnings review
Growth Hits a Wall, Profits Turn to Losses
Health In Tech's Q1 2026 report flashes major warning signs. The explosive growth narrative from 2025 has suddenly stalled, with revenue decelerating to a mere 9.4% YoY increase (down from 90% in Q3 and 53% in Q4). Worse, the company's profitability is rapidly reversing. Gross margins collapsed from 67% to 51%, and skyrocketing operating expenses drove Adjusted EBITDA to a $1.3 million loss. Management reiterated a bullish 35-50% growth target for the full year, but the current trajectory and aggressive cash burn (requiring a new $7M PIPE raise) heavily contradict that optimism.
🐂 Bull Case
The company enters Q2 with $22.9 million in contracted revenue for the remaining three quarters, providing a solid baseline. Distribution partners also grew a healthy 29.5% YoY to 896.
Management expects new capabilities rolled out in January 2026 (including 100+ stop-loss plans and a 3-year rate stabilization program) to deliver meaningful revenue in H2.
🐻 Bear Case
Gross margins plunged to 51.4% from 66.8% a year ago, while total operating expenses jumped 36.7%. The leverage model is currently broken.
With only 9.4% growth in Q1, achieving the reiterated 35-50% full-year growth target requires an immediate and massive re-acceleration that the current contracted backlog does not fully support.
⚖️ Verdict: 🔴
Bearish. The sudden top-line deceleration combined with collapsing margins and a return to cash-burning operations completely undermines the previously established narrative of scalable, profitable hyper-growth.
Key Themes
The Guidance Gap
There is a glaring contradiction between Q1's actual data and management's FY26 guidance. Revenue grew just 9.4% in Q1. Yet, the company reiterated FY26 guidance of $45-$50M, implying 35-50% YoY growth. With $8.8M booked and $22.9M contracted, the company needs to find $13.3M to $18.3M in entirely new, uncontracted revenue over the next 9 months just to hit the target. This requires a dramatic re-acceleration.
Underwriting Modeling (ICE) Collapsing
A deep dive into segment performance reveals a severe reversal in the core Underwriting Modeling (ICE) segment. Revenue dropped 37.5% YoY, falling from $2.35M in 25Q1 to $1.47M in 26Q1. SMR (Fees) carried the quarter, growing 29% to $7.3M, but the ICE contraction is a major red flag regarding the underlying health of the underwriting platform's adoption.
Cost Structure Spiraling Out of Control
The narrative of an efficient, high-margin software platform is cracking. Cost of Revenues surged 60% YoY, crushing gross profit, which actually declined in absolute terms from $5.35M to $4.51M despite higher sales. Simultaneously, Sales & Marketing expenses more than doubled (+110%) to $2.29M. The company is spending exponentially more to generate significantly lower growth.
Distribution Network Expanding Steadily
The company's primary growth engine—its partner network—remains intact. Distribution partners (brokers, TPAs, agencies) increased by 29.5% to 896. Continued engagement across this growing network is critical to bridging the gap to FY26 guidance.
Agile Technology Development Cycle
Management highlights their AI-driven platform's ability to deploy new features in 1-2 quarters, a stark contrast to the 1-2 years required by legacy insurance carriers. This agility allowed them to launch a suite of 100+ pre-configured stop-loss plans in January, intended to reduce sales friction.
Three-Year Rate Stabilization Program
First teased in 2025, the new three-year rate stabilization program is designed to deliver budget predictability for employers facing significant macro inflation in healthcare costs. Management expects this program to start delivering meaningful revenue in the second half of 2026.
Dilutive Capital Raise to Fund Cash Burn
The rapid deterioration in profitability forced Health In Tech to return to the capital markets. In March, they completed a Private Investment in Public Equity (PIPE) financing, securing $7M in gross proceeds ($6.38M net). While it shores up the balance sheet ($10.3M cash), it underscores the company's inability to self-fund its current aggressive spending strategy.
Other KPIs
Reversing violently from a positive $0.53 million in Q1 2025. The core business is currently burning cash to fund an explosion in accounts receivable (which jumped $3.0M) and higher operating losses.
This represents the aggregate contractual value of self-funded health plans placed through the platform. This is a critical metric for understanding the total volume flowing through the company's ecosystem, even if HIT only captures a fraction of it as revenue.
Guidance
Accelerating significantly versus the Q1 run rate. The midpoint implies 42.5% YoY growth for the full year. Given the severe deceleration to 9.4% in Q1, achieving this will require a massive ramp-up in H2 driven entirely by new product launches and large-group adoption.
Key Questions
ICE Segment Collapse
Underwriting modeling revenue dropped 37% year-over-year. What specifically caused this sharp contraction in your core technological offering, and is this a structural shift in how carriers are using your platform?
Bridging the Guidance Gap
You printed 9% growth in Q1 but maintain guidance of 35-50% for the year. Given that Q1 is historically your strongest season due to January renewals, what exactly gives you the visibility to project such a dramatic re-acceleration in Q2 through Q4?
Path to Gross Margin Recovery
Gross margins collapsed from 67% to 51%, and cost of revenues jumped 60%. What were the specific drivers of these costs (e.g., hosting, third-party data), and are these elevated costs the new baseline for the business?